| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
MAO-A (Ki = 4.2 μM); MAO-B (Ki = 46 μM)
|
|---|---|
| ln Vitro |
In human brain synaptosomes and human liver mitochondria, bifemelane inhibits MAO-A in a dose-dependent manner with Kis values of 4.2±0.2 and 14.1±0.7 μM, respectively [1]. In human brain synaptosomes and human liver mitochondria, bifemelane inhibits MAO-B activity in a dose-dependent manner with Kis values of 46.0±3.6 and 65.2±7.0 μM, respectively [1].
|
| ln Vivo |
Bifemelane (20-80 mg/kg; intraperitoneal injection) decreases exploratory activity in the open field test in a dose-dependent manner [3]. In the forced swim test, Bifemelane (20-80 mg/kg; intraperitoneal injection) shortens the immobility period [3], however the dose dependence is not evident and the maximum dosage of 20 mg/kg has been attained.
|
| Enzyme Assay |
4-(O-Benzylphenoxy)-N-methylbutylamine (Bifemelane, BP-N-methylbutylamine), a new psychotropic drug, was found to inhibit monoamine oxidase (MAO) in human brain synaptosomes. It inhibited type A MAO (MAO-A) competitively and type B (MAO-B) noncompetitively. BP-N-methylbutylamine had a much higher affinity to MAO-A than an amine substrate, kynuramine, and it was a more potent inhibitor of MAO-A than of MAO-B. The Ki values of MAO-A and -B were determined to be 4.20 and 46.0 microM, respectively, while the Km values of MAO-A and -B with kynuramine were 44.1 and 90.0 microM, respectively. The inhibition of MAO-A and -B by BP-N-methylbutylamine was found to be reversible by dialysis of the incubation mixture. MAO-A in human placental and liver mitochondria and in a rat clonal pheochromocytoma cell line, PC12h, was inhibited competitively by BP-N-methylbutylamine, while MAO-B in human liver mitochondria was inhibited noncompetitively, as in human brain synaptosomes. BP-N-methylbutylamine was not oxidized by MAO-A and -B. The effects of other BP-N-methylalkylamines, such as BP-N-methylethylamine, -propylamine, and -pentanylamine, on MAO activity were examined. BP-N-methylbutylamine was the most potent inhibitor of MAO-A, and BP-N-methylethylamine and -propylamine inhibited MAO-B competitively, whereas BP-N-methylbutylamine and -pentanylamine inhibited it noncompetitively. Inhibition of these BP-N-methylalkylamines on MAO-A and -B is discussed in relation to their chemical structure[1].
|
| Animal Protocol |
Animal/Disease Models: Wistar male rats (230-270 g) Reserpine-induced hypothermia [3]
Doses: 20, 40, 80 mg/kg Route of Administration: Single intraperitoneal (ip) injection Experimental Results: Reserpine-induced hypothermia If it is too low, the maximum temperature will be diminished by 10℃. |
| References |
|
| Additional Infomation |
This study aims to explore emerging antidepressants that promise positive milestones, significant improvements, and substantial impacts in the treatment of patients with depression. Furthermore, this study elucidates the relationship between the agomelatine paradox and other novel antidepressants. These emerging antidepressants include: selective monoamine oxidase inhibitors (MAOIs), such as bifemethylene blue, pirlinindole, toloxacin, selegiline, rasagiline, and safenamide; serotonin-norepinephrine reuptake inhibitors (SNRIs), such as ansofasin, nefopam, and levamisole; and norepinephrine reuptake inhibitors (NRIs), such as reboxetine, veloxacin, teniloxazine (also known as sulfadiazine or sufoxacin), and atormoxetine. Verazordone (a partial agonist of serotonin 5-HT1A autoreceptor with serotonin reuptake inhibition [SPARI]); vortioxetine (a serotonin receptor antagonist with serotonin reuptake inhibition [SARI]); atypical antipsychotics such as olanzapine, quetiapine, risperidone, lurasidone, aripiprazole, and buripiperazole; N-methyl-D-aspartate (NMDA) glutamatergic neurotransmitter blockers such as ketamine, CP-101,606 (trosoprodil), GLYX-13 (lapastine), NRX-1074 (apilimustine), and riluzole. Agomelatine (a melatonin MT1 and MT2 receptor agonist and a selective 5-HT2B and 5-HT2C receptor antagonist [MASSA]) remains a complex drug that does not belong to any existing antidepressant class, and its pharmacological properties make it unsuitable for classification into another new class of antidepressants, contrary to previous reports. Finally, this review specifically advocates for the inclusion of atypical antipsychotics and NMDA-glutamatergic ion receptor blockers in a new class of antidepressants, as they play important clinical roles in the treatment of depression [2].
|
| Molecular Formula |
C18H24CLNO
|
|---|---|
| Molecular Weight |
305.846
|
| Exact Mass |
305.155
|
| Elemental Analysis |
C, 70.69; H, 7.91; Cl, 11.59; N, 4.58; O, 5.23
|
| CAS # |
62232-46-6
|
| Related CAS # |
Bifemelane;90293-01-9
|
| PubChem CID |
6917789
|
| Appearance |
White to yellow solid powder
|
| Boiling Point |
395.4ºC at 760 mmHg
|
| Melting Point |
117-121°C
|
| Flash Point |
169.2ºC
|
| LogP |
4.848
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
21
|
| Complexity |
238
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2.Cl
|
| InChi Key |
MEAHDXWXNNDSAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H23NO.ClH/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16;/h2-6,9-12,19H,7-8,13-15H2,1H3;1H
|
| Chemical Name |
4-(2-benzylphenoxy)-N-methylbutan-1-amine hydrochloride
|
| Synonyms |
MCI-2016 MCI 2016 MCI2016Bifemelane Bifemelanum Bifemelane HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~817.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2696 mL | 16.3479 mL | 32.6958 mL | |
| 5 mM | 0.6539 mL | 3.2696 mL | 6.5392 mL | |
| 10 mM | 0.3270 mL | 1.6348 mL | 3.2696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA